Opendata, web and dolomites

RD-MRI NETWORK SIGNED

BRIDGING THE GAP BETWEEN ACADEMIA & CLINICAL TRIALS FOR THE DEVELOPMENT OF RARE DISEASE TREATMENTS VIA NUCLEAR MAGNETIC RESONANCE IMAGING (MRI)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RD-MRI NETWORK" data sheet

The following table provides information about the project.

Coordinator
CONSULTANTS FOR RESEARCH IN IMAGING AND SPECTROSCOPY SCRL 

Organization address
address: CHAUSSEE DE LANNOY 31
city: TOURNAI
postcode: 7503
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Belgium [BE]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2020-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CONSULTANTS FOR RESEARCH IN IMAGING AND SPECTROSCOPY SCRL BE (TOURNAI) coordinator 50˙000.00

Map

 Project objective

Rare diseases affect 36 million citizens in the EU with 75% of patients being children and 30% dying under the age of five. 94% of the 8,000 rare diseases lack approved treatments and the EU has created financial incentives for pharmaceutical companies (PhC) to develop suitable orphan drugs but they face difficulties through increasingly high development risks where a failed drug trial can cost €1.8bn on average. In order to lower their costs, PhCs outsource development work to Contractual Research Organizations (CRO) who specialise in specific task such as drug discovery or clinical trials but these CROs have significant limitations such as a lack of modern Nuclear Magnetic Resonance Imaging (MRI) methodologies, EMA/FDA compliance, contacts to clinical sites and restricted access to rare disease patient groups. We present MRI NETWORK, the first solution which bridges the gap between PhCs and clinical sites by providing an online network of expert clinical sites, full trial design, the most advanced MRI methodologies and smart automated MRI data processing & coordination. This project will be fundamental in bringing our technology to full market readiness and reach the 150,000 clinical sites and 36 million rare disease patients in the EU. Our company, CRIS, has been involved in 30 clinical trials in the past 20 years and with our extensive commercial network of clinical sites, academic experts, pharmaceutical companies and the relevant regulatory institutions, we expect to generate €15.4m in profits with an ROI of 6.7 over 3 years. RD-MRI NETWORK creates a new market for clinical trials and MRI services in the EU and, next to 17 direct jobs, we will create 500 new skilled jobs by allowing academics to receive adequate compensation for MRI services and increase industry collaborations in academia.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RD-MRI NETWORK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RD-MRI NETWORK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

HUD (2018)

COMMERCIALIZING THE FIRST HEAD-UP-DISPLAY FOR OFF-HIGHWAY VEHICLES

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More